Literature DB >> 20086256

Barriers to insulin initiation: the translating research into action for diabetes insulin starts project.

Andrew J Karter1, Usha Subramanian, Chandan Saha, Jesse C Crosson, Melissa M Parker, Bix E Swain, Howard H Moffet, David G Marrero.   

Abstract

OBJECTIVE: Reasons for failing to initiate prescribed insulin (primary nonadherence) are poorly understood. We investigated barriers to insulin initiation following a new prescription. RESEARCH DESIGN AND METHODS: We surveyed insulin-naïve patients with poorly controlled type 2 diabetes, already treated with two or more oral agents who were recently prescribed insulin. We compared responses for respondents prescribed, but never initiating, insulin (n = 69) with those dispensed insulin (n = 100).
RESULTS: Subjects failing to initiate prescribed insulin commonly reported misconceptions regarding insulin risk (35% believed that insulin causes blindness, renal failure, amputations, heart attacks, strokes, or early death), plans to instead work harder on behavioral goals, sense of personal failure, low self-efficacy, injection phobia, hypoglycemia concerns, negative impact on social life and job, inadequate health literacy, health care provider inadequately explaining risks/benefits, and limited insulin self-management training.
CONCLUSIONS: Primary adherence for insulin may be improved through better provider communication regarding risks, shared decision making, and insulin self-management training.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20086256      PMCID: PMC2845015          DOI: 10.2337/dc09-1184

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   17.152


Insulin is typically recommended for patients with type 2 diabetes if they have failed to achieve adequate glycemic control despite treatment with multiple oral agents at maximal dose (1), especially when β-cell function declines (2,3). Despite the known benefits of insulin, many patients fail to begin insulin treatment (4). In a previous study (5), we followed a cohort of patients with diabetes who were prescribed new glucose-lowering medications. We observed that 4.5% of insulin-naïve patients who were prescribed insulin never filled that prescription (were primary nonadherent) and an additional 25.5% had zero refills (early-stage nonpersistence). Thus, one in three insulin-naïve patients who were prescribed insulin never became ongoing users. A patient's reluctance to initiate insulin has been dubbed psychological insulin resistance (PIR) (6). Current understanding of PIR is based largely on surveys of insulin-naïve patients queried about their hypothetical willingness to initiate insulin (7,8). However, the reasons why patients fail to initiate therapy after actually agreeing to and receiving a first prescription for insulin have not been explored. In this study, we evaluate barriers and attitudes among insulin-naïve patients who had failed to initiate newly prescribed insulin therapy (i.e., primary nonadherent) versus those who did initiate insulin therapy (i.e., primary adherent).

RESEARCH DESIGN AND METHODS

Subjects for this study of insulin adherence came from Kaiser Permanente Northern California (Kaiser) and Horizon Blue Cross Blue Shield of New Jersey and were participants in the Translating Research Into Action for Diabetes (TRIAD) Study (7), an ongoing study of quality of care and self-care for people with diabetes in managed-care settings across the U.S. We identified poorly controlled, insulin-naïve and insulin-eligible type 2 diabetic patients receiving a new electronic prescription for insulin. Eligibility criteria included 1) newly prescribed insulin during August 2007 to February 2008, 2) Two or more diagnoses for type 2 diabetes 18 months prior to the new insulin prescription, 3) no insulin use in prior 2 years, 4) already taking one oral agent at maximum and a second oral agent at maximal/submaximal dose, 5) two consecutive A1Cs ≥8% 2.5–12 months apart or last A1C ≥9%, and 6) two or more clinic visits in the previous 12 months. Patients aged >85 years, with limited English proficiency, life-limiting malignancy, hospice care enrollment, significant cognitive deficits, psychiatric illness (excluding major depression), or visual impairment limiting insulin self-administration, were excluded. We identified a random sample of eligible subjects who were primary adherent (at least one dispensing of insulin) and primary nonadherent (not dispensed the newly prescribed insulin within 60 days of the prescribing date) from pharmacy records. Computer-assisted telephone interviews and self-administered mailed surveys were used to collect insulin treatment, provider communication, self-management training, health literacy (8), and depressive symptoms (9). We used standard American Association for Public Opinion Research (AAPOR) algorithms for calculating response rates (10). The human subjects review boards in the TRIAD translational research centers involved with this study (Kaiser, the University of Medicine and Dentistry of New Jersey, and Indiana University) approved this study.

RESULTS

We mailed an invitation letter to 195 and 186 primary nonadherent and adherent subjects, respectively, following approval of their providers. Sixty-nine nonadherent and 100 adherent patients responded to the survey and are the basis for this study. The AAPOR response rate, which assumes that those who could not be contacted for eligibility confirmation had the same proportion of eligibility as those contacted, was 60% overall (50% in the nonadherent and 68% in adherent group). The cooperation rate (percent survey completion among eligible subjects we were able to reach) was 98% (100% in the nonadherent and 92% in adherent group). None of the patient characteristics differed significantly between adherent and nonadherent subjects. Nonadherent subjects had a mean age of 61 years and 35% were women, 49% were of a minority ethnic heritage, 37% had an income <$40,000, 33% had no college education, and 48% were retired or unemployed. Adherent subjects had a mean age of 58 years and 47% were women, 54% were of minority ethnic heritage, 22% had an income <$40,000, 31% had no college education, and 33% were retired or unemployed. Among nonadherent patients, the most commonly cited reasons for failing to initiate insulin included the following reasons: The patient planned to change health behaviors instead of starting insulin (25%), injection phobia (13%), negative impact on work (9%), concerns about long-term medication use (9%), inconvenience (6%), and not believing insulin was needed (6%). Nonadherent patients believed that people who require insulin “have not taken care of themselves in the past” (47%) and that “taking insulin can cause…” blindness (20%), renal failure (32%), amputations (15%), heart attacks or strokes (19%), and early death (19%). In all, 35% of the insulin-nonadherent group reported that they believed insulin causes harm (at least one of the possible complications listed above). Compared with adherent patients, nonadherent patients expressed significantly more concern about their inability to adjust insulin dosage, the impact on social life and work, injection pain, and side effects, particularly hypoglycemia (Table 1). Significantly more nonadherent patients reported problems learning about their medical condition because of difficulty understanding written information (inadequate health literacy) and claimed providers failed to adequately explain insulin's risk and benefits. Substantially fewer nonadherent patients reported receiving insulin self-management training from their doctor, nurse, health educator, or a class.
Table 1

Comparisons of survey responses for primary nonadherent and adherent patients newly prescribed insulin*

NonadherentAdherent
Stated moderate/extreme concerns (versus not at all or a little concerned) regarding:
    The cost of insulin shots12/51 (24)22/82 (27)
    How insulin shots might restrict your activities or “hold back” your lifestyle20/54 (37)20/82 (24)
    The additional burden associated with home monitoring of blood sugar15/59 (25)19/82 (23)
    Difficulty giving insulin due to things like poor eyesight, shakiness, or arthritis23/55 (42)24/81 (30)
    Your ability to make dose adjustments22/54 (41)10/82 (12)
    How insulin shots may negatively impact your social life21/56 (38)15/82 (18)
    A negative impact on your job (if you work outside the home)15/45 (33)6/72 (8)
    The insulin shots being painful17/56 (30)12/82 (15)
    Possible side effects of giving yourself shots24/55 (44)10/81 (12)
    Insulin shots causing you to have low blood glucose22/51 (43)13/81 (16)
Patient-provider interactions and communication
    Never or only sometimes (versus usually or always) felt confidence or trust in personal physician that manages diabetes11/68 (16)11/97 (11)
    Moderately or extremely difficult (versus not at all difficult or a little difficult) to talk with doctor about concerns about diabetes medication or insulin9/66 (14)10/100 (10)
    Risks and benefits were not very well or not well at all (versus somewhat well or very well) explained37/67 (55)37/96 (39)
    Inadequate health literacy: sometimes, often, or always (versus never or rarely); have problems learning about medical condition because of difficulty understanding written information (not including problems due to poor vision)35/69 (51)30/99 (30)
How was the insulin self-management training provided
    Doctor trained1/66 (2)13/77 (17)
    Insulin self-management class5/66 (8)31/77 (40)
    Nurse trained4/66 (6)33/77 (43)

Data are n/N (%).

*N takes into account missing responses.

†Significant contrasts (P < 0.05).

Comparisons of survey responses for primary nonadherent and adherent patients newly prescribed insulin* Data are n/N (%). *N takes into account missing responses. †Significant contrasts (P < 0.05).

CONCLUSIONS

Among poorly controlled patients with type 2 diabetes newly prescribed insulin, the major predictors of insulin nonadherence included plans to improve health behaviors in lieu of starting insulin, negative impact on social and work life, injection phobia, and concerns about side effects or hypoglycemia. Nonadherent patients often blamed themselves, believing prior poor self-management caused the current need for insulin and erroneously conceptualized insulin as itself the cause of future complications. These patient-level findings are consistent with previous studies of attitudes about insulin (11,12). Not previously reported is our finding that nonadherent patients frequently felt their provider had not adequately explained the risks and benefits of insulin. The importance of provider communication is underscored by the association between insulin initiation and health literacy (13). Primary nonadherence likely also reflects inadequate shared decision making or lack of self-management training. Interventions for PIR need to address both provider- and system-level factors (14–16).
  14 in total

1.  Psychological insulin resistance: the patient perspective.

Authors:  William Polonsky
Journal:  Diabetes Educ       Date:  2007 Jul-Aug       Impact factor: 2.140

2.  New prescription medication gaps: a comprehensive measure of adherence to new prescriptions.

Authors:  Andrew J Karter; Melissa M Parker; Howard H Moffet; Ameena T Ahmed; Julie A Schmittdiel; Joe V Selby
Journal:  Health Serv Res       Date:  2009-06-03       Impact factor: 3.402

Review 3.  The Translating Research Into Action for Diabetes (TRIAD) study: a multicenter study of diabetes in managed care.

Authors: 
Journal:  Diabetes Care       Date:  2002-02       Impact factor: 19.112

4.  Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  David M Nathan; John B Buse; Mayer B Davidson; Robert J Heine; Rury R Holman; Robert Sherwin; Bernard Zinman
Journal:  Diabetes Care       Date:  2006-08       Impact factor: 19.112

Review 5.  Overcoming psychological barriers to insulin use in type 2 diabetes.

Authors:  Stephen A Brunton; Stephen N Davis; Susan M Renda
Journal:  Clin Cornerstone       Date:  2006

6.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

Authors:  R C Turner; C A Cull; V Frighi; R R Holman
Journal:  JAMA       Date:  1999-06-02       Impact factor: 56.272

7.  Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire.

Authors:  R L Spitzer; K Kroenke; J B Williams
Journal:  JAMA       Date:  1999-11-10       Impact factor: 56.272

8.  Measuring psychological insulin resistance: barriers to insulin use.

Authors:  Mary E Larkin; Virginia A Capasso; Chien-Lin Chen; Ellen K Mahoney; Barbara Hazard; Enrico Cagliero; David M Nathan
Journal:  Diabetes Educ       Date:  2008 May-Jun       Impact factor: 2.140

9.  Closing the loop: physician communication with diabetic patients who have low health literacy.

Authors:  Dean Schillinger; John Piette; Kevin Grumbach; Frances Wang; Clifford Wilson; Carolyn Daher; Krishelle Leong-Grotz; Cesar Castro; Andrew B Bindman
Journal:  Arch Intern Med       Date:  2003-01-13

10.  Racial/ethnic differences in concerns about current and future medications among patients with type 2 diabetes.

Authors:  Elbert S Huang; Sydney E S Brown; Nidhi Thakur; Lisabeth Carlisle; Edward Foley; Bernard Ewigman; David O Meltzer
Journal:  Diabetes Care       Date:  2008-11-18       Impact factor: 17.152

View more
  81 in total

Review 1.  The role of comfort and discomfort in insulin therapy.

Authors:  Ronnie Aronson
Journal:  Diabetes Technol Ther       Date:  2012-04-26       Impact factor: 6.118

2.  Acute hypoglycemia causes depressive-like behaviors in mice.

Authors:  Min Jung Park; Samuel W Yoo; Brian S Choe; Robert Dantzer; Gregory G Freund
Journal:  Metabolism       Date:  2011-08-04       Impact factor: 8.694

3.  Patients' Future Expectations for Diabetes and Hypertension Treatments: "Through the Diet… I Think This is Going to Go Away."

Authors:  Paige C Fairchild; Aviva G Nathan; Michael Quinn; Elbert S Huang; Neda Laiteerapong
Journal:  J Gen Intern Med       Date:  2016-10-11       Impact factor: 5.128

4.  Efficacy and safety of insulin lispro protamine suspension as basal supplementation in patients with type 2 diabetes.

Authors:  Dario Giugliano; Katherine Esposito
Journal:  Ther Adv Endocrinol Metab       Date:  2012-06       Impact factor: 3.565

5.  Diabetes Self-management Education and Support in Type 2 Diabetes: A Joint Position Statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics.

Authors:  Margaret A Powers; Joan Bardsley; Marjorie Cypress; Paulina Duker; Martha M Funnell; Amy Hess Fischl; Melinda D Maryniuk; Linda Siminerio; Eva Vivian
Journal:  Clin Diabetes       Date:  2016-04

6.  Development and Validation of a Tool to Identify Patients With Type 2 Diabetes at High Risk of Hypoglycemia-Related Emergency Department or Hospital Use.

Authors:  Andrew J Karter; E Margaret Warton; Kasia J Lipska; James D Ralston; Howard H Moffet; Geoffrey G Jackson; Elbert S Huang; Donald R Miller
Journal:  JAMA Intern Med       Date:  2017-10-01       Impact factor: 21.873

7.  A Behavioral Perspective of Therapeutic Inertia: A Look at the Transition to Insulin Therapy.

Authors:  Susan J Guzman
Journal:  Diabetes Spectr       Date:  2020-02

8.  Communication and medication refill adherence: the Diabetes Study of Northern California.

Authors:  Neda Ratanawongsa; Andrew J Karter; Melissa M Parker; Courtney R Lyles; Michele Heisler; Howard H Moffet; Nancy Adler; E Margaret Warton; Dean Schillinger
Journal:  JAMA Intern Med       Date:  2013-02-11       Impact factor: 21.873

9.  Impact of inpatient diabetes management, education, and improved discharge transition on glycemic control 12 months after discharge.

Authors:  Deborah J Wexler; Catherine C Beauharnais; Susan Regan; David M Nathan; Enrico Cagliero; Mary E Larkin
Journal:  Diabetes Res Clin Pract       Date:  2012-10-01       Impact factor: 5.602

Review 10.  AFREZZA® (insulin human) Inhalation Powder: A Review in Diabetes Mellitus.

Authors:  Esther S Kim; Greg L Plosker
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.